It takes an R&D village to fight a pandemic

Gervais Tougas never thought he’d have to face this again. In 2003, while serving as a division head in one of McMaster University’s teaching hospitals, a SARS outbreak in nearby Toronto, Canada tossed his organization into uncharted waters. Like its coronavirus cousin, COVID-19, SARS posed an imminent, deadly threat to public health. To ensure the safety of the hospital and the surrounding community, the entire organization had to pivot from its usual medical practice and prepare itself to weather the outbreak.

…

/by

Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14


 

  • Tabrecta (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic NSCLC with a mutation that leads to MET exon 14 skipping (METex14)1 
  • ~4,000-5,000 patients are diagnosed with METex14 metastatic NSCLC each year in the US and may face poor prognosis due to presence of the mutation2-3
     
  • Tabrecta demonstrated an overall response rate of 68% and 41% in treatment-naive and previously treated METex14 patients, …
/by